Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors
    • Author Guidelines
  • Content
    • Current Issue
    • Complete Issue PDF
    • Archive
    • 20th Anniversary Special Edition
    • Topic/Program Collections
    • Blog
    • Questions from NeoReviews
  • CME/MOC
    • CME Quizzes
    • MOC Claiming
    • NeoReviewsPlus
    • Board Review Study Guide
  • Multimedia
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors
    • Author Guidelines
  • Content
    • Current Issue
    • Complete Issue PDF
    • Archive
    • 20th Anniversary Special Edition
    • Topic/Program Collections
    • Blog
    • Questions from NeoReviews
  • CME/MOC
    • CME Quizzes
    • MOC Claiming
    • NeoReviewsPlus
    • Board Review Study Guide
  • Multimedia
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
American Academy of Pediatrics
Article

Antifungal Agents and Fungal Prophylaxis in the Neonate

Stephen D. Kicklighter
NeoReviews December 2002, 3 (12) e249-e255; DOI: https://doi.org/10.1542/neo.3-12-e249
Stephen D. Kicklighter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Download PDF
  • ABCS: amphotericin B colloidal dispersion
  • ABLC: amphotericin B lipid complex
  • AmpB: amphotericin B
  • CSF: cerebrospinal fluid
  • DOL: day of life
  • 5-FC: flucytosine
  • GI: gastrointestinal
  • VLBW: very low-birthweight (<1,500 g)

Objectives

After completing this article, readers should be able to:

  1. Delineate the third most common cause of late-onset sepsis in very low-birthweight infants.

  2. Describe the primary predictors for successful treatment of potential fungal sepsis and culture-positive sepsis.

  3. List the gold standard for antifungal therapy in the neonate.

  4. Compare and contrast liposomal amphotericin B and amphotericin B and describe the neonates in whom liposomal amphotericin B should be used.

  5. Describe the situation in which antifungal prophylaxis may be appropriate.

Introduction

Among the 6,956 very low-birthweight (VLBW) (<1,500 g) infants reported to the National Institute of Child Health and Human Development between 1998 and 2000, Candida albicans was the third most frequent organism isolated (76/1313, 6%), following coagulase-negative Staphylococcus and S aureus, in episodes of late-onset sepsis. (1) Candida sp were responsible for 12.2% of first episodes of late-onset disease. (1) Because of a mortality rate as high as 25% (32% in the recent study by Stoll and associates (1)) for septicemia and 36% for meningitis as well as an 11-fold increase in the incidence of such infection over the previous 15 years, early initiation of therapy is imperative. (2)(3) Unfortunately, the mean delay between initial positive blood culture and commencement of antifungal treatment varies from 2.1±1.3 days to 5.1±3 days, and a significant number of infants are not diagnosed until autopsy. (4) Delayed treatment may reflect not only an increased risk of mortality, but also increased rates of intraventricular hemorrhage, chronic lung disease, retinopathy of prematurity requiring surgical therapy, and up to a fourfold increase in long-term neurodevelopmental delays. Early recognition and therapy as well as the removal of central lines remain the most important predictors of successful treatment. (5)

In a recent study by Rowen and colleagues (6) in which questionnaires were distributed to United States-based members of …

Individual Login

Log in
You will be redirected to aap.org to login or to create your account.

Institutional Login

via Institution

You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Offer Reprints

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

NeoReviews
Vol. 3, Issue 12
1 Dec 2002
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antifungal Agents and Fungal Prophylaxis in the Neonate
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Antifungal Agents and Fungal Prophylaxis in the Neonate
Stephen D. Kicklighter
NeoReviews Dec 2002, 3 (12) e249-e255; DOI: 10.1542/neo.3-12-e249

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Antifungal Agents and Fungal Prophylaxis in the Neonate
Stephen D. Kicklighter
NeoReviews Dec 2002, 3 (12) e249-e255; DOI: 10.1542/neo.3-12-e249
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Objectives
    • Introduction
    • Polyenes
    • Flucytosine
    • Azoles
    • Newer Agents
    • Prophylaxis
    • Summary
    • References
  • Figures & Data
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Clinical Microbiology of Bacterial and Fungal Sepsis in Very-Low-Birth-Weight Infants
  • Google Scholar

More in this TOC Section

  • Neonatal Dermatology: The Normal, the Common, and the Serious
  • Protection of the Newborn Through Vaccination in Pregnancy
  • Update on the Use of Intravenous Immunoglobulin in Pregnancy
Show more Article

Similar Articles

Subjects

  • Pharmacology
    • Pharmacology
  • Journal Info
  • Editorial Board
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • NeoReviewsPlus
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
  • NeoReviews® and NeoReviewsPlus™ are supported, in part, through an educational grant from Abbott Nutrition, a division of Abbott Laboratories, Inc.
American Academy of Pediatrics

© 2021 American Academy of Pediatrics